On May 28, Affymax Inc. received a determination letter from Nasdaq indicating that Nasdaq believes that the company should be delisted, Affymax announced in a regulatory filing. Specifically, Nasdaq said that Affymax is operating as a “public shell” and following the voluntary recall of Omontys, the company no longer has an operating business.

Affymax said in the filing that it does not plan to appeal the determination by Nasdaq. Trading in the Company’s common stock will be suspended at the opening of business on June 6, 2013.